Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Targeting the p300/CBP Axis in Lethal Prostate Cancer

Open access
Welti, Jonathan, Sharp, Adam, Brooks, Nigel, Yuan, Wei, McNair, Christopher, Chand, Saswati N., Pal, Abhijit, Figueiredo, Ines, Riisnaes, Ruth, Gurel, Bora, Rekowski, Jan, Bogdan, Denisa, West, William, Young, Barbara, Raja, Meera, Prosser, Amy, Lane, Jordan, Thomson, Stuart, Worthington, Jenny, Onions, Stuart, Shannon, Jonathan, Paoletta, Silvia, Brown, Richard, Smyth, Don, Harbottle, Gareth W., Gil, Veronica S., Miranda, Susana, Crespo, Mateus, Ferreira, Ana, Pereira, Rita, Tunariu, Nina, Carreira, Suzanne, Neeb, Antje J., Ning, Jian, Swain, Amanda, Taddei, David, SU2C/PCF International Prostate Cancer Dream Team, Schiewer, Matthew J., Knudsen, Karen E., Pegg, Neil, de Bono, Johann S.·2021·Cancer Discovery

Abstract

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR activity, including the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal prostate cancer. Herein, we validate targeting p300/CBP as a therapeutic strategy for lethal prostate cancer and describe CCS1477, a novel small-molecule inhibitor of the p300/CBP conserved bromodomain. We show that CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC–regulated gene expression. In AR-SV–driven models, CCS1477 has antitumor activity, regulating AR and C-MYC signaling. Early clinical studies suggest that CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression. Overall, CCS1477 shows promise for the treatment of patients with advanced prostate cancer. Significance: Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR coactivators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, inhibits growth and AR activity in CRPC models, and can affect metastatic CRPC target expression in serial clinical biopsies. See related commentary by Rasool et al., p. 1011. This article is highlighted in the In This Issue feature, p. 995

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0751

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 275

Metadata

Authors
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., Rekowski, J., Bogdan, D., West, W., Young, B., Raja, M., Prosser, A., Lane, J., Thomson, S., Worthington, J., Onions, S., Shannon, J., Paoletta, S., Brown, R., Smyth, D., Harbottle, G. W., Gil, V. S., Miranda, S., Crespo, M., Ferreira, A., Pereira, R., Tunariu, N., Carreira, S., Neeb, A. J., Ning, J., Swain, A., Taddei, D., SU2C/PCF International Prostate Cancer Dream Team, Schiewer, M. J., Knudsen, K. E., Pegg, N., & de Bono, J. S.
Venue
Cancer Discovery
Published
2021-01-11
Volume
11
Issue
5
Pages
1118-1137
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3119572339
Cited by
275
References
12
FWCI
24.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the p300/CBP Axis in Lethal Prostate Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0751
The paper
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., Rekowski, J., Bogdan, D., West, W., Young, B., Raja, M., Prosser, A., Lane, J., Thomson, S., Worthington, J., . . . de Bono, J. S. (2021). Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.